ArticleEuropean radiology2026
Right ventricular and biatrial CMR strain analysis detects myocardial functional impairment after breast cancer therapy.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiovascular Imaging for the Early Detection of Cardiotoxicity from Emerging Cancer Therapies: Mechanistic Insights Across the Pediatric and Adult Spectrum.Journal of personalized medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate breast cancer therapy-related myocardial cardiotoxicity by analyzing right ventricular (RV), left atrial (LA), and right atrial (RA) function using cardiovascular magnetic resonance feature tracking (CMR-FT). MATERIALS AND
methodsThis prospective single-center study involved 38 female breast cancer patients with a mean age of 50 ± 11 years, who received systemic anthracycline chemotherapy. CMR was performed in all patients before initiating therapy (at baseline (BL)) and after a 12-month follow-up (FU). FT was utilized to evaluate the RV global longitudinal (GLS), radial (GRS), and circumferential strain (GCS), as well as the biatrial reservoir, booster, and conduit strain. Paired t-tests were used to assess the differences in strain values from BL to FU.
resultsThe mean RV GLS of all patients was significantly attenuated at FU compared to BL (-25.2 ± 3.9% at BL vs -20.6 ± 4.4% at FU, p < 0.001), whereas RV GRS and GCS showed no significant change. LA reservoir strain was significantly reduced at FU (24.1 ± 3.2 at BL vs 22.7 ± 3.3% at FU, p = 0.005), while LA booster and conduit strain showed non-significant change. Similarly, RA reservoir strain decreased significantly from BL to FU (24.9 ± 3.3% at BL vs 23.2 ± 2.9% at FU, p = 0.019), whereas RA booster and conduit strain did not significantly change from BL to FU.
conclusionsCancer therapy-related cardiac dysfunction (CTRCD) is not confined to the LV but affects the RV and the atria as well. Changes in RV GLS and LA/RA reservoir strain could serve as additional markers of subclinical cardiotoxicity in breast cancer patients. KEY POINTS: Question The role of RV and biatrial strain in detecting CTRCD is unclear. Findings Biatrial reservoir strain and RV GLS were significantly attenuated after breast cancer therapy. Clinical relevance RV GLS and biatrial reservoir strain might serve as early markers of subclinical cardiotoxicity after breast cancer therapy and should thus be routinely determined in patients with suspected CTRCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.